【摘要】 目的:探讨奎硫平治疗难治性抑郁症的增效作用及安全性。方法:58例难治性抑郁症患者分为研究组(抗抑郁药联合奎硫平治疗)和对照组(单用抗抑郁药治疗)各29例。观察6周。于治疗前及治疗1、2、4和6周采用汉密尔顿抑郁量表(HAMD)、汉密尔顿焦虑量表(HAMA)评定疗效;以治疗中出现的症状量表(TESS)评定不良反应。结果:两组治疗后HAMD和HAMA评分均较治疗前有显著降分(P<0.05或P<0.001);以研究组HAMD减分率自治疗1周起、HAMA减分率自治疗4周起均显著高于对照组(P<0.01或P<0.001)。两组治疗各周TESS评分差异均无统计学意义(P>0.05)。结论:奎硫平治疗难治性抑郁症增效作用明显且安全。更多还原

【Abstract】 Objective:To explore the efficacy and safety of quetiapine augmentation of antidepressants on treatment-resitant depression. Method:Using the random control according to the order of hospitalization,58 patients with treatment-resistant depression were assigned to quetiapine group (quetiapine plus antidepressant) and control group (antidepressant alone).The study lasted for 6 weeks.The effects and side effects were assessed with Hamilton depression scale (HAMD),Hamilton anxiety scale (HAMA) and treatment emergent symptom scale (TESS) respectively at baseline,week 1,2,4 and 6. Results:The total scores of HAMD and HAMA were significantly decreased after treatment in two groups (P<0.05 or P<0.001).The quetiapine group had more HAMD from week one as well as HAMA from week four rate of decreation than the control group (P<0.01 or P<0.001).There was no significant difference of TESS scores between two groups at each week (P>0.05). Conclusion:Quetiapine can be effective and safe in adjunctive treatment of patients with treatment-resistant depression更多还原